INMED PHARMACEUTICALS INC. Revenue from Contract with Customer, Including Assessed Tax
INMED PHARMACEUTICALS INC. (INM) reported Revenue from Contract with Customer, Including Assessed Tax of $1.37 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-29.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2023-09-29
- INMED PHARMACEUTICALS INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $1.37M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|
| 2023-06-30 | $1.37M 10-K · filed 2023-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |